菜单
Telephone sharing button Contact Us linkedin sharing button LinkedIn wechat sharing button YouTube wechat sharing button Twitter mailbox sharing button info@wuxibiologics.com
arrow_left sharing button
arrow_right sharing button

Press Releases

WuXi Biologics Enters into an Agreement with Terumo on Leverkusen DP Plant
May 14, 2025
WuXi Biologics Enters into an Agreement with Terumo on Leverkusen DP Plant

Leverkusen, Germany, May 14, 2025 – WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced that it has entered into an agreement with Terumo Corporation that Terumo will take over WuXi Biologics’ drug product (DP) plant in Leverkusen, Germany for EUR 150 million. The transaction is expected to be concluded in 2025, subject to the satisfaction of customary closing conditions.

 

Divesting the Leverkusen facility is a strategic step in aligning with the company’s long-term growth to enhance agility, scale diversified solutions for its global clients, and address emerging needs worldwide. This decision will allow WuXi Biologics to exclusively focus on building large-scale global DP manufacturing capacities in Singapore while optimizing returns on assets for future growth.

 

As a result, WuXi Biologics has completed the strategic review of all sites and will focus on building and developing its current sites.

 

About WuXi Biologics

 

WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.

 

With over 12,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of December 31, 2024, WuXi Biologics is supporting 817 integrated client projects, including 21 in commercial manufacturing (excluding COVID CMO projects).

 

WuXi Biologics regards sustainability as the cornerstone of long-term business growth. The company continuously drives green technology innovations to offer advanced end-to-end Green CRDMO solutions for its global partners while consistently achieving excellence in Environment, Social and Governance (ESG). Committed to creating shared value, it collaborates with all stakeholders to foster positive social and environmental impacts and promote responsible practices that empower the entire value chain.

 

For more information about WuXi Biologics, please visit: www.wuxibiologics.com.

    

Contacts
     

Business

info@wuxibiologics.com

 

Media
PR@wuxibiologics.com